Navigation Links
Morphine for Chest Pain Increases Death Risk

While patients hospitalized for a heart attack have long been treated with morphine to relieve chest pain, an analysis by researchers from the Duke Clinical Research Institute has shown that these patients have almost a 50 percent higher risk of dying.

The researchers call for a randomized clinical trial to confirm their analysis. Meanwhile, they advise cardiologists to begin treatment with sufficient doses of nitroglycerin to relieve pain before resorting to morphine.

In their analysis of the clinical data and outcomes of more than 57,000 high-risk heart attack patients -- 29.8 percent of whom received morphine within the first 24 hours of hospitalization -- the researchers found that those who received morphine had a 6.8 percent death rate, compared to 3.8 percent for those receiving nitroglycerin. The increase in mortality persisted even after adjustment for the patients' baseline clinical risk.

The results of the Duke were published as a fast-track article in the American Heart Journal.

"The results of this analysis raise serious concerns about the safety of the routine use of morphine in this group of heart patients," said Duke cardiologist Trip Meine, M.D., the study's lead author. "Since randomized clinical trials evaluating the safety or effectiveness of morphine for these patients have not been conducted, official guidelines for its use are based solely on expert conjecture. Given the adverse outcomes associated with morphine use found in our analysis, a randomized clinical trial is in order."

Morphine was first used to relieve the chest pain associated with heart attacks in 1912 and has been used regularly ever since. Nitroglycerin has been used for more than 130 years for the relief of chest pain, also known as unstable angina. It works by relaxing blood vessels and allowing blood flow to increase.

"Nitroglycerin has a physiological effect that may, at least temporarily, influence the underlying ischemia," Me ine said. "Morphine, on the other hand, doesn't do anything about what is actually causing the pain. It just masks it, and may, in fact, make the underlying disease worse.

"Morphine has the well-known and potentially harmful side effects of depressing respiration, reducing blood pressure and slowing heart rate," he continued. "These side effects could explain the worse outcomes in patients whose heart function has already been compromised by disease."

For their analysis, the researchers consulted the nationwide quality improvement initiative named CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology and AHA Guidelines) The registry continually collects data from more than 400 hospitals on outcomes and on the use of proven drugs and procedures used to restore blood flow to the heart.

From this registry, the researchers identified 57,039 high-risk patients with non-ST-segment elevation myocardial infarction (non-STEMI), a categorization of heart attack based on electrocardiogram (ECG) readings. These patients typically arrive at emergency rooms with chest pain, but often will not have telltale signs of a heart attack on the initial ECG. They might be diagnosed with a heart attack only when the results of the blood tests are reported a few hours later.

The researchers found that patients who were given morphine had 48 percent higher risk of dying and 34 percent higher risk of suffering another heart attack while in the hospital.

"This increase in mortality was present in every subgroup of patients we studied," Meine said. "What we found interesting was that patients given morphine were more likely to receive evidence-based medicine, were more likely to be treated by a cardiologist and were more likely to receive an invasive cardiac procedure."

Meine recommended that physicians with hospitalized heart attack patients sho uld begin with nitroglycerin therapy to control pain.

"Our recommendation is that patients should receive the full dose of nitroglycerin," he said. "Based on our analysis, morphine should be the last resort after else has been tried."

While patients with acute STEMI are at higher risk of dying within 30 days of their hospital stay, patients with non-STEMI actually have a higher risk of dying six months and one year after initial hospital presentation. It is estimated that about 1.3 million Americans are hospitalized each year with non-STEMI.

CRUSADE continuously gathers data from participating U.S. hospitals on treatments for patients with non-STEMI and provides quarterly feedback to hospitals with the ultimate goal of improving adherence to the ACC/AHA treatment guidelines and patient outcomes.

The CRUSADE registry is funded by Millennium Pharmaceuticals, Cambridge, Mass., and Schering Corp, Kenilworth, N.J. Bristol-Meyers Squibb/Sanofi Pharmaceuticals Partnership, NY, provided an unrestricted grant in support of CRUSADE.


'"/>

Source:DukeHealth


Related biology news :

1. Morphine makes lasting -- and surprising -- change in the brain
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. New Estimates For The Causes Of Child Deaths Worldwide
4. Measles Deaths Worldwide Drop By Nearly 40% Over Five Years
5. Are U.S. Flu Death Figures More PR Than Science?
6. Brain Scans Reveal How Gene May Boost Schizophrenia Risk
7. Male Combat Veterans Rank High In Heart Disease Risk
8. FDA: Highly Unlikely Green Tea Lowers Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... of foodborne pathogens today announced the appointment of Mary Duseau ... , the Company,s President and CEO since 2009, who will assume ... changes are effective today. In addition, Ms. Duseau will ... ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
(Date:1/17/2017)... , Jan. 17, 2017 Research ... report "Molecular Diagnostics - Technologies, Markets and Companies" ... ... diagnostics has increased remarkably during the past few years. More ... developing molecular diagnostics and 342 of these are profiled in ...
(Date:1/17/2017)...  Northwell Health today announced a collaboration with ... research. As New ... Northwell Health diagnoses and treats 19,000 new cancer ... Germany -based oncology research company working ... greatly expand cancer biobanking activities within Northwell Health ...
Breaking Biology Technology: